Abbott-MiniMed Flex Diabetes System Ships with 80% Time in Range

For diabetes care teams and health IT leaders, the August 17 U.S. launch of MiniMed Flex integrated with Abbott's Instinct sensor signals a shift toward interoperable, patient-managed insulin delivery. The system's reported 80% Time in Range and over 90% overnight could reduce nocturnal hypoglycemia and alarm fatigue if these real-world results hold across broader populations—a key clinical and workflow consideration.

On August 17, 2026, MiniMed Group, Inc. (NASDAQ: MMED) announced that its MiniMed Flex automated insulin delivery system is commercially shipping in the United States with Abbott Laboratories' (NYSE: ABT) Instinct continuous glucose sensor. The integration unites two notable diabetes technologies: MiniMed Flex, described as MiniMed's smallest and only app-controlled automated insulin delivery system, and Instinct, which the company calls the world's smallest 15-day CGM. The system holds 300 units of insulin, connects to a 7-day Extended infusion set, and is driven by SmartGuard technology and Meal Detection automation. In real-world data cited by the companies, the combined system reaches 80% Time in Range and over 90% overnight, figures that are likely to resonate with patients, clinicians, and payers.

“

The healthcare giant reaffirmed its 6.5%–7.5% organic sales growth target and raised full-year EPS guidance to $5.45–$5.60, bolstered by medical device performance and double-digit electrophysiology growth.

The diabetes technology market has been moving toward longer-wear sensors, smaller pumps, and more autonomous algorithms. Abbott's Instinct sensor extends wear to 15 days, reducing insertion burden and potentially lowering daily sensor cost if coverage is adequate. MiniMed Flex adds an extended 7-day infusion set, which cuts the number of pump site changes relative to many pumps requiring more frequent replacements. This matters operationally for patients and care teams, but it also sets a new benchmark for competing automated insulin delivery systems from Medtronic, Tandem Diabetes Care, and Insulet.

Financially, the partnership joins two very different companies. Abbott reported Q2 2026 revenue of $12.6 billion, a 13.0% reported increase, with adjusted EPS of $1.31. The healthcare giant reaffirmed its 6.5%–7.5% organic sales growth target and raised full-year EPS guidance to $5.45–$5.60, bolstered by medical device performance and double-digit electrophysiology growth. MiniMed Group, by contrast, is a pure-play diabetes technology company with a market capitalization of roughly $5.67 billion and no comparable quarterly revenue disclosed in the analysis; it is scheduled to report fiscal Q1 2027 results on September 1, 2026. That earnings report will be the first formal financial check following the U.S. launch of MiniMed Flex, and investors and providers will look for revenue, gross margin, and installed-base signals.

From a clinical standpoint, the headline metric is the 80% Time in Range and over 90% overnight. While these are real-world data rather than a randomized controlled trial, they align with the broader push in diabetes care to treat Time in Range as a more actionable glycemic metric than A1C alone. Higher overnight TIR reduces nocturnal hypoglycemia episodes and associated alarm fatigue, two persistent burdens for people with insulin-dependent diabetes. For health systems adopting remote monitoring and IT-integrated diabetes management, the system's app-controlled design and connected data stream may also improve care team visibility and patient-reported outcomes. However, health leaders should request independent, peer-reviewed validation of these metrics before making formulary or technology purchasing decisions.